SAN DIEGO, June 04, 2007 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing antibacterial drugs for the treatment of serious infections, announced today that Kenneth F. Bartizal, Ph.D. has joined the company as Chief Development Officer. Dr. Bartizal, formerly Executive Director and Head, Infectious Disease Research for Merck, made major contributions to the development and registration of multiple marketed drugs including INVANZ(R), and CANCIDAS(R). He will assume responsibility for the development of Trius' pipeline of antibacterial drug candidates including the Company's lead candidate, TR-701, a best-in-class oxazolidinone that is anticipated to begin human clinical trials by the end of this year.
